Autolus Therapeutics (AUTL) Share-based Compensation (2018 - 2025)

Autolus Therapeutics (AUTL) has reported Share-based Compensation for 8 consecutive years, with $3.4 million the latest figure, recorded in Q4 2025.

• Quarterly Share-based Compensation fell 44.76% year-over-year to $3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.4 million (down 6.68% YoY) and the FY2025 annual result came in at $14.4 million, down 6.68% from the prior year.
• Share-based Compensation retreated to $3.4 million in Q4 2025 per AUTL's latest filing, from $3.8 million in the prior quarter.
• Over the last five years, Share-based Compensation for AUTL reached as high as $27.9 million in Q3 2021 and fell as low as -$18.6 million in Q4 2021.
• A 5-year average of $4.7 million and a median of $3.4 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2021 — Share-based Compensation tumbled 267.64% — and 2024, when it soared 9993.65%.
• Year by year, Share-based Compensation stood at -$18.6 million in 2021, then soared by 118.38% to $3.4 million in 2022, then sank by 101.84% to -$63000.0 in 2023, then surged by 9993.65% to $6.2 million in 2024, then slumped by 44.76% to $3.4 million in 2025.
• According to Business Quant data, Share-based Compensation over the past three periods registered $3.4 million, $3.8 million, and $4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.